All sponsors

Alexion Pharmaceuticals, Inc. $AZN

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS25
PHASE 3 / 2-320
RECRUITING9
READOUTS ≤12 MONTHS7
READOUT SLIPPED >6 MO32%

Delay Index: of 22 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +3.7 months). See all sponsors →

Open Alexion Pharmaceuticals, Inc. on the live radar map → 📅 $AZN readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
CALYPSO
NCT05778071
P3Active, not recruitingChronic Hypoparathyroidism; Endocrine System Diseases1652024-11-15
CAEL-101
NCT04512235
P3Active, not recruitingAL Amyloidosis2812025-04-08 (+32 mo)
CAEL-101
NCT04504825
P3Active, not recruitingAL Amyloidosis1252025-05-10 (+33 mo)
ALXN1720
NCT05556096
P3Active, not recruitingGeneralized Myasthenia Gravis2602025-05-27 (-1 mo)
HICKORY
NCT06079281
P3Active, not recruitingHypophosphatasia1242025-07-09 (-3 mo)
CHESTNUT
NCT06079372
P3Active, not recruitingHypophosphatasia432025-07-23 (+5 mo)
I CAN
NCT06291376
P3Active, not recruitingImmunoglobulin A Nephropathy; IgAN5842026-01-05 (-2 mo)
MULBERRY
NCT06079359
P3Active, not recruitingHypophosphatasia302026-01-06 (+7 mo)
Ravulizumab
NCT05346354
P2/3Active, not recruitingNeuromyelitis Optica Spectrum Disorder122026-06-22 (+4 mo)
Ravulizumab
NCT05644561
P3Active, not recruitingGeneralized Myasthenia Gravis; gMG122026-07-15
Danicopan
NCT05389449
P3Active, not recruitingParoxysmal Nocturnal Hemoglobinuria802026-08-24 (+8 mo)
ECU-NMO-304
NCT06724809
P3Active, not recruitingNMOSD; Neuromyelitis Optica Spectrum Disorders212026-12-07 (-4 mo)
Gefurulimab
NCT06607627
P3RecruitingGeneralized Myasthenia Gravis; gMG122026-12-15 (-4 mo)
Danicopan
NCT06449001
P3RecruitingParoxysmal Nocturnal Hemoglobinuria; PNH62027-05-28 (+4 mo)
AUTUMN
NCT07157787
P2RecruitingPrimary Membranous Nephropathy302027-07-02 (+4 mo)
Ravulizumab
NCT07596784
P3RecruitingGeneralized Myasthenia Gravis; gMG202027-08-24
Tarperprumig
NCT07160608
P2Active, not recruitingAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis782027-10-11
CONCORD
NCT06744647
P2Active, not recruitingAntibody-Mediated Rejection; Kidney Transplantation472027-10-11 (+6 mo)
AWAKE
NCT06830798
P3RecruitingDelayed Graft Function; DGF4502027-11-30 (-3 mo)
DepleTTR-CM
NCT06183931
P3Active, not recruitingTransthyretin Amyloid Cardiomyopathy11822027-12-06 (-11 mo)
Ravulizumab
NCT07557420
P3RecruitingNMOSD; Neuromyelitis Optica Spectrum Disorder192028-09-19
Ravulizumab
NCT07024563
P3RecruitingIgAN; IgAVN362028-11-29 (+13 mo)
ALACRITY
NCT07081646
P1/2RecruitingRelapsed AL Amyloidosis; Refractory AL Amyloidosis912029-08-15
LTSAFE-ALXN
NCT07789483
P3Not yet recruitingTransthyretin Amyloid Cardiomyopathy (ATTR-CM)11802030-07-11
DCMRestore
NCT07218887
P1/2RecruitingBAG3 Mutation Associated Dilated Cardiomyopathy62032-01-27 (+18 mo)